Symbols / GLSI $24.94 +8.86% Greenwich LifeSciences, Inc.
GLSI Chart
About
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also develops FLAMINGO-01, which is in Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
Fundamentals
Scroll to Statements| Market Cap | 345.53M | Enterprise Value | 313.60M | Income | -19.48M | Sales | — | Book/sh | 0.16 | Cash/sh | 0.28 |
| Dividend Yield | — | Payout | 0.00% | Employees | 4 | IPO | — | P/E | — | Forward P/E | -30.41 |
| PEG | — | P/S | — | P/B | 157.85 | P/C | — | EV/EBITDA | -16.01 | EV/Sales | — |
| Quick Ratio | 2.35 | Current Ratio | 2.35 | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | -1.46 | EPS next Y | -0.82 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-04-30 | ROA | -254.19% | ROE | -5.43% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 13.85M | Shs Float | 6.57M | Short Float | 21.91% |
| Short Ratio | 8.18 | Short Interest | — | 52W High | 34.10 | 52W Low | 7.78 | Beta | 1.53 | Avg Volume | 213.52K |
| Volume | 121.14K | Target Price | $47.50 | Recom | Strong_buy | Prev Close | $22.91 | Price | $24.94 | Change | 8.86% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$47.50
Mean price target
2. Current target
$24.94
Latest analyst target
3. DCF / Fair value
$-1.76
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$24.94
Low
$45.00
High
$50.00
Mean
$47.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-30 | main | HC Wainwright & Co. | Buy → Buy | $50 |
| 2025-04-21 | main | HC Wainwright & Co. | Buy → Buy | $39 |
| 2025-02-11 | reit | HC Wainwright & Co. | Buy → Buy | $38 |
| 2024-08-23 | main | HC Wainwright & Co. | Buy → Buy | $38 |
| 2024-05-22 | reit | HC Wainwright & Co. | Buy → Buy | $36 |
| 2024-02-28 | reit | HC Wainwright & Co. | Buy → Buy | $36 |
| 2024-02-20 | main | HC Wainwright & Co. | Buy → Buy | $36 |
| 2023-04-10 | reit | HC Wainwright & Co. | — → Buy | $38 |
| 2021-09-01 | init | HC Wainwright & Co. | — → Buy | $78 |
| 2021-01-27 | init | Aegis Capital | — → Buy | $75 |
| 2021-01-26 | init | Aegis Capital | — → Buy | $75 |
- Nasdaq flags Greenwich LifeSciences over delayed 2025 annual report - Stock Titan Wed, 22 Apr 2026 21
- $GLSI stock is up 9% today. Here's what we see in our data. - Quiver Quantitative Wed, 22 Apr 2026 14
- Why Did GLSI Stock Rise Pre-Market Today? - Stocktwits Mon, 20 Apr 2026 18
- Why did GLSI stock rise pre-market today? - MSN Mon, 20 Apr 2026 15
- GLSI (Greenwich LifeSciences Inc.) reports narrow Q3 2025 EPS beat, shares climb 2.36 percent on positive investor sentiment. - Secondary Offering - Cổng thông tin điện tử Tỉnh Sơn La Wed, 22 Apr 2026 11
- (GLSI) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily ue, 21 Apr 2026 09
- Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing - The Manila Times Wed, 22 Apr 2026 21
- Is Greenwich LifeSciences (GLSI) stock still attractive (Bullish Sentiment) 2026-04-18 - Stock Idea Sharing Hub - Xã Thanh Hà Sun, 19 Apr 2026 02
- Why did GLSI stock rise in the pre-market? | Tap to know more | Inshorts - Inshorts Mon, 20 Apr 2026 05
- Breast cancer immunotherapy shows 4x immune response in Phase III data - Stock Titan Mon, 20 Apr 2026 10
- $GLSI stock is up 17% today. Here's what we see in our data. - Quiver Quantitative Mon, 26 Jan 2026 08
- Greenwich LifeSciences sold stock faster than it spent cash in Q1 - Stock Titan ue, 14 Apr 2026 07
- $GLSI stock is down 11% today. Here's what we see in our data. - Quiver Quantitative Fri, 02 Jan 2026 08
- $GLSI stock is up 12% today. Here's what we see in our data. - Quiver Quantitative Wed, 14 Jan 2026 08
- Breast cancer immunotherapy patent push aims to widen eligible patients - Stock Titan ue, 07 Apr 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
16.01
+71.66%
|
9.33
+16.01%
|
8.04
+74.87%
|
4.60
|
| Research And Development |
|
12.95
+68.24%
|
7.70
+18.89%
|
6.48
+81.93%
|
3.56
|
| Selling General And Administration |
|
3.06
+87.80%
|
1.63
+4.13%
|
1.56
+50.67%
|
1.04
|
| General And Administrative Expense |
|
3.06
+87.80%
|
1.63
+4.13%
|
1.56
+50.67%
|
1.04
|
| Other Gand A |
|
3.06
+87.80%
|
1.63
+4.13%
|
1.56
+50.67%
|
1.04
|
| Total Expenses |
|
16.01
+71.66%
|
9.33
+16.01%
|
8.04
+74.87%
|
4.60
|
| Operating Income |
|
-16.01
-71.66%
|
-9.33
-16.01%
|
-8.04
-74.87%
|
-4.60
|
| Total Operating Income As Reported |
|
-16.01
-71.66%
|
-9.33
-16.01%
|
-8.04
-74.87%
|
-4.60
|
| EBITDA |
|
-16.01
-71.68%
|
-9.32
-16.02%
|
-8.04
-74.93%
|
-4.59
|
| Normalized EBITDA |
|
-16.01
-71.68%
|
-9.32
-16.02%
|
-8.04
-74.93%
|
-4.59
|
| Reconciled Depreciation |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| EBIT |
|
-16.01
-71.66%
|
-9.33
-16.01%
|
-8.04
-74.87%
|
-4.60
|
| Net Income |
|
-15.79
-77.57%
|
-8.89
-13.63%
|
-7.83
-71.21%
|
-4.57
|
| Pretax Income |
|
-15.79
-77.57%
|
-8.89
-13.63%
|
-7.83
-71.21%
|
-4.57
|
| Net Non Operating Interest Income Expense |
|
0.22
-48.86%
|
0.44
+102.80%
|
0.22
+685.68%
|
0.03
|
| Net Interest Income |
|
0.22
-48.86%
|
0.44
+102.80%
|
0.22
+685.68%
|
0.03
|
| Interest Income Non Operating |
|
0.22
-48.86%
|
0.44
+102.80%
|
0.22
+685.68%
|
0.03
|
| Interest Income |
|
0.22
-48.86%
|
0.44
+102.80%
|
0.22
+685.68%
|
0.03
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-15.79
-77.57%
|
-8.89
-13.63%
|
-7.83
-71.21%
|
-4.57
|
| Net Income From Continuing Operation Net Minority Interest |
|
-15.79
-77.57%
|
-8.89
-13.63%
|
-7.83
-71.21%
|
-4.57
|
| Net Income From Continuing And Discontinued Operation |
|
-15.79
-77.57%
|
-8.89
-13.63%
|
-7.83
-71.21%
|
-4.57
|
| Net Income Continuous Operations |
|
-15.79
-77.57%
|
-8.89
-13.63%
|
-7.83
-71.21%
|
-4.57
|
| Normalized Income |
|
-15.79
-77.57%
|
-8.89
-13.63%
|
-7.83
-71.21%
|
-4.57
|
| Net Income Common Stockholders |
|
-15.79
-77.57%
|
-8.89
-13.63%
|
-7.83
-71.21%
|
-4.57
|
| Diluted EPS |
|
-1.21
-75.36%
|
-0.69
-13.11%
|
-0.61
-74.29%
|
-0.35
|
| Basic EPS |
|
-1.21
-75.36%
|
-0.69
-13.11%
|
-0.61
-74.29%
|
-0.35
|
| Basic Average Shares |
|
13.01
+1.30%
|
12.85
-0.51%
|
12.91
-0.23%
|
12.94
|
| Diluted Average Shares |
|
13.01
+1.30%
|
12.85
-0.51%
|
12.91
-0.23%
|
12.94
|
| Diluted NI Availto Com Stockholders |
|
-15.79
-77.57%
|
-8.89
-13.63%
|
-7.83
-71.21%
|
-4.57
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
4.09
-41.47%
|
6.99
-48.10%
|
13.48
-50.48%
|
27.22
|
| Current Assets |
|
4.09
-41.45%
|
6.99
-48.10%
|
13.47
-50.49%
|
27.20
|
| Cash Cash Equivalents And Short Term Investments |
|
4.09
-41.45%
|
6.99
-48.10%
|
13.47
-50.49%
|
27.20
|
| Cash And Cash Equivalents |
|
4.09
-41.45%
|
6.99
-48.10%
|
13.47
-50.49%
|
27.20
|
| Cash Financial |
|
4.09
-41.45%
|
6.99
-48.10%
|
13.47
-50.49%
|
27.20
|
| Total Non Current Assets |
|
0.00
-67.00%
|
0.01
-40.12%
|
0.01
-28.63%
|
0.01
|
| Goodwill And Other Intangible Assets |
|
0.00
-67.00%
|
0.01
-40.12%
|
0.01
-28.63%
|
0.01
|
| Other Intangible Assets |
|
0.00
-67.00%
|
0.01
-40.12%
|
0.01
-28.63%
|
0.01
|
| Total Liabilities Net Minority Interest |
|
1.56
+429.79%
|
0.29
+11.98%
|
0.26
-31.74%
|
0.39
|
| Current Liabilities |
|
1.56
+429.79%
|
0.29
+11.98%
|
0.26
-31.74%
|
0.39
|
| Payables And Accrued Expenses |
|
1.25
+325.76%
|
0.29
+11.98%
|
0.26
-31.74%
|
0.39
|
| Payables |
|
1.18
+359.41%
|
0.26
+16.06%
|
0.22
+0.00%
|
0.22
|
| Accounts Payable |
|
1.18
+359.41%
|
0.26
+16.06%
|
0.22
+0.00%
|
0.22
|
| Current Accrued Expenses |
|
0.08
+99.31%
|
0.04
-9.44%
|
0.04
-74.40%
|
0.16
|
| Current Deferred Liabilities |
|
0.31
|
—
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Stockholders Equity |
|
2.53
-62.18%
|
6.70
-49.29%
|
13.21
-50.75%
|
26.83
|
| Common Stock Equity |
|
2.53
-62.18%
|
6.70
-49.29%
|
13.21
-50.75%
|
26.83
|
| Capital Stock |
|
0.01
+2.37%
|
0.01
+0.00%
|
0.01
-2.28%
|
0.01
|
| Common Stock |
|
0.01
+2.37%
|
0.01
+0.00%
|
0.01
-2.28%
|
0.01
|
| Share Issued |
|
13.15
+2.37%
|
12.85
+0.00%
|
12.85
-2.28%
|
13.15
|
| Ordinary Shares Number |
|
13.15
+2.37%
|
12.85
+0.00%
|
12.85
-2.28%
|
13.15
|
| Additional Paid In Capital |
|
68.67
+20.37%
|
57.05
+4.35%
|
54.67
-9.58%
|
60.47
|
| Retained Earnings |
|
-66.15
-31.35%
|
-50.36
-21.44%
|
-41.47
-23.26%
|
-33.65
|
| Total Equity Gross Minority Interest |
|
2.53
-62.18%
|
6.70
-49.29%
|
13.21
-50.75%
|
26.83
|
| Total Capitalization |
|
2.53
-62.18%
|
6.70
-49.29%
|
13.21
-50.75%
|
26.83
|
| Working Capital |
|
2.53
-62.18%
|
6.70
-49.30%
|
13.21
-50.76%
|
26.82
|
| Invested Capital |
|
2.53
-62.18%
|
6.70
-49.29%
|
13.21
-50.75%
|
26.83
|
| Net Tangible Assets |
|
2.53
-62.18%
|
6.70
-49.30%
|
13.21
-50.76%
|
26.82
|
| Tangible Book Value |
|
2.53
-62.18%
|
6.70
-49.30%
|
13.21
-50.76%
|
26.82
|
| Dueto Related Parties Current |
|
—
|
—
|
—
|
0.00
|
| Interest Payable |
|
—
|
—
|
0.22
+0.00%
|
0.22
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-7.27
-12.16%
|
-6.48
-4.49%
|
-6.20
-44.47%
|
-4.29
|
| Cash Flow From Continuing Operating Activities |
|
-7.27
-12.16%
|
-6.48
-4.49%
|
-6.20
-44.47%
|
-4.29
|
| Net Income From Continuing Operations |
|
-15.79
-77.57%
|
-8.89
-13.63%
|
-7.83
-71.21%
|
-4.57
|
| Depreciation Amortization Depletion |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Amortization Cash Flow |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Depreciation And Amortization |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Amortization Of Intangibles |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Stock Based Compensation |
|
7.25
+205.01%
|
2.38
+36.37%
|
1.74
+163.99%
|
0.66
|
| Change In Working Capital |
|
1.27
+3916.78%
|
0.03
+125.76%
|
-0.12
+68.26%
|
-0.39
|
| Change In Payables And Accrued Expense |
|
0.96
+2944.49%
|
0.03
+125.76%
|
-0.12
+68.26%
|
-0.39
|
| Change In Accrued Expense |
|
0.04
+1052.58%
|
-0.00
+96.75%
|
-0.12
-186.37%
|
0.14
|
| Change In Payable |
|
0.92
+2497.03%
|
0.04
|
—
|
-0.53
|
| Change In Account Payable |
|
0.92
+2497.03%
|
0.04
|
0.00
+100.00%
|
-0.53
|
| Change In Other Working Capital |
|
0.31
|
—
|
—
|
—
|
| Financing Cash Flow |
|
4.37
|
0.00
+100.00%
|
-7.54
-365.79%
|
2.84
|
| Cash Flow From Continuing Financing Activities |
|
4.37
|
0.00
+100.00%
|
-7.54
-365.79%
|
2.84
|
| Net Common Stock Issuance |
|
4.37
|
0.00
+100.00%
|
-7.54
|
0.00
|
| Common Stock Payments |
|
—
|
0.00
+100.00%
|
-7.54
|
0.00
|
| Repurchase Of Capital Stock |
|
—
|
0.00
+100.00%
|
-7.54
|
0.00
|
| Proceeds From Stock Option Exercised |
|
—
|
—
|
0.00
-100.00%
|
3.11
|
| Net Other Financing Charges |
|
—
|
—
|
—
|
-0.28
|
| Changes In Cash |
|
-2.90
+55.28%
|
-6.48
+52.84%
|
-13.74
-843.35%
|
-1.46
|
| Beginning Cash Position |
|
6.99
-48.10%
|
13.47
-50.49%
|
27.20
-5.08%
|
28.66
|
| End Cash Position |
|
4.09
-41.45%
|
6.99
-48.10%
|
13.47
-50.49%
|
27.20
|
| Free Cash Flow |
|
-7.27
-12.16%
|
-6.48
-4.49%
|
-6.20
-44.47%
|
-4.29
|
| Change In Interest Payable |
|
—
|
—
|
0.00
-100.00%
|
0.04
|
| Common Stock Issuance |
|
4.37
|
0.00
|
—
|
3.11
|
| Issuance Of Capital Stock |
|
4.37
|
0.00
|
—
|
3.11
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-01-15 View
- 42026-01-14 View
- 42026-01-05 View
- 42026-01-02 View
- 42025-12-19 View
- 8-K2025-12-18 View
- 42025-11-28 View
- 42025-11-17 View
- 10-Q2025-11-14 View
- 42025-11-12 View
- 42025-11-04 View
- 10-Q2025-08-14 View
- 8-K2025-07-24 View
- 10-Q2025-05-20 View
- 42025-04-29 View
- 42025-04-22 View
- 10-K2025-04-15 View
- 42025-04-08 View
- 42025-04-07 View
- 42025-01-13 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|